General MedicationsNASALStandard

RYALTRIS

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE

Standard Dose

0.025MG/SPRAY;0.665MG/SPRAY

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Prescription

Summary

Approval overview RYALTRIS is listed in Drugs@FDA under application 211746 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE Form and strength SPRAY, METERED;NASAL - 0.025MG/SPRAY;0.665MG/SPRAY Sponsor GLENMARK SPECLT Submission history Latest submission status date: 2023-08-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview RYALTRIS is listed in Drugs@FDA under application 211746 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE Form and strength SPRAY, METERED;NASAL - 0.025MG/SPRAY;0.665MG/SPRAY Sponsor GLENMARK SPECLT Submission history Latest submission status date: 2023-08-29 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Prescription
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.